Oncology News | pharmaphorum

News

Astellas strikes $1.7bn SIRP drug deal with Elpiscience

Astellas has struck a deal with fellow Japanese pharma company Elpiscience to develop up to four cancer immunotherapies that work by revving up the activity of macrophages

News

BMS strikes again, with $4.1bn RayzeBio takeover bid

Bristol-Myers Squibb is having a busy holiday period, signing a $4.1 billion deal to acquire cancer drug developer RayzeBio – its second multibillion-dollar M&A deal i

News

AZ makes another cell therapy play with $1.2bn Gracell buy

AstraZeneca has lined up a $1.2 billion takeover deal for Chinese biotech Gracell Biotechnologies, bolting a series of cell therapies for cancer and autoimmune diseases on

News

Let’s Talk Prostate Cancer calls for action by MEPs

An organisation representing the interests of patients with prostate cancer has published a manifesto ahead of the EU elections next year, calling for more screening for t

News

Sanofi drops lung cancer ADC tusamitamab ravtansine

French drugmaker Sanofi has halted the development of its antibody-drug conjugate (ADC) tusamitamab ravtansine after the drug failed a phase 3 trial in non-small cell lung

News

GSK taps Hansoh for another cancer ADC candidate

GSK has turned to China’s Hansoh Pharma to add another antibody-drug conjugate (ADC) to its oncology pipeline, this time licensing a B7-H3-targeting candidate for $185 million upfront

Astellas strikes $1.7bn SIRP drug deal with Elpiscience

BMS strikes again, with $4.1bn RayzeBio takeover bid

AZ makes another cell therapy play with $1.2bn Gracell buy

Let’s Talk Prostate Cancer calls for action by MEPs

Sanofi drops lung cancer ADC tusamitamab ravtansine

GSK taps Hansoh for another cancer ADC candidate

Amazon puts $100m into global health drive

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks